Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Hernandez

Showing results (21-30 of 88) with videos related to

Pageof 9
Sort By:
Clinical Pharmacology and Therapeutics|May 1, 2021
When Can We Trust Real-World Data To Evaluate New Medical Treatments?Gregory E Simon, Andrew B Bindman, Nancy A Dreyer, et al.
Circulation|January 31, 2018
Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart FailureDharam J Kumbhani, Gregg C Fonarow, Paul A Heidenreich, et al.
Journal of Thrombosis and Thrombolysis|September 8, 2019
Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trialWalter Ageno, Renato D Lopes, Megan K Yee, et al.
American Heart Journal|December 17, 2008
Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The GuidelinesAmit Sachdeva, Christopher P Cannon, Prakash C Deedwania, et al.
Clinical Pharmacology and Therapeutics|April 25, 2021
When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?Gregory E Simon, Richard Platt, Jonathan H Watanabe, et al.
Journal of Thrombosis and Haemostasis : JTH|August 9, 2019
Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or moreWalter Ageno, Renato D Lopes, Megan K Yee, et al.
JAMA Network Open|February 8, 2020
Prospective and External Evaluation of a Machine Learning Model to Predict In-Hospital Mortality of Adults at Time of AdmissionNathan Brajer, Brian Cozzi, Michael Gao, et al.
American Heart Journal|April 13, 2019
Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patientsDaniel L Edmonston, Jingjing Wu, Roland A Matsouaka, et al.
JACC. Heart Failure|May 19, 2015
Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?Paul A Heidenreich, Vivian Tsai, Haikun Bao, et al.
ESC Heart Failure|May 17, 2024
Implications of trial eligibility in patients with heart failure with mildly reduced or preserved ejection fractionAnthony E Peters, Robert M Clare, Karen Chiswell, et al.
Pageof 9

Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Clinical Pharmacology and Therapeutics|May 1, 2021
When Can We Trust Real-World Data To Evaluate New Medical Treatments?Gregory E Simon, Andrew B Bindman, Nancy A Dreyer, et al.
Circulation|January 31, 2018
Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart FailureDharam J Kumbhani, Gregg C Fonarow, Paul A Heidenreich, et al.
Journal of Thrombosis and Thrombolysis|September 8, 2019
Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trialWalter Ageno, Renato D Lopes, Megan K Yee, et al.
American Heart Journal|December 17, 2008
Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The GuidelinesAmit Sachdeva, Christopher P Cannon, Prakash C Deedwania, et al.
Clinical Pharmacology and Therapeutics|April 25, 2021
When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?Gregory E Simon, Richard Platt, Jonathan H Watanabe, et al.
Journal of Thrombosis and Haemostasis : JTH|August 9, 2019
Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or moreWalter Ageno, Renato D Lopes, Megan K Yee, et al.
JAMA Network Open|February 8, 2020
Prospective and External Evaluation of a Machine Learning Model to Predict In-Hospital Mortality of Adults at Time of AdmissionNathan Brajer, Brian Cozzi, Michael Gao, et al.
American Heart Journal|April 13, 2019
Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patientsDaniel L Edmonston, Jingjing Wu, Roland A Matsouaka, et al.
JACC. Heart Failure|May 19, 2015
Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?Paul A Heidenreich, Vivian Tsai, Haikun Bao, et al.
ESC Heart Failure|May 17, 2024
Implications of trial eligibility in patients with heart failure with mildly reduced or preserved ejection fractionAnthony E Peters, Robert M Clare, Karen Chiswell, et al.
Pageof 9